Abstract
The efficacy of intranasally administered neostigmine was tested in 22 patients with generalized myasthenia gravis (MG). Topical therapy to the highly vascularized oropharynx proved to be quickly effective in 5-15 min both clinically and electrophysiologically. Twenty-eight MG patients were then recruited from different centres and their morning doses of oral pyridostigmine were substituted with intranasal neostigmine over a period of 2 or 3 weeks. Intranasal neostigmine proved to be equally efficacious in this regimen. No side-effect was noted even in 4 patients treated in this way for 1 year. Intranasal administration of anti-acetylcholinesterase may be very beneficial: (1) for patients with irregular absorption of oral doses; (2) early in the morning and every time a fast and temporary effect is needed; (3) in bulbar impairment and emergencies, in which a handy atomizer may be life-saving.
| Original language | English |
|---|---|
| Pages (from-to) | 165-169 |
| Number of pages | 5 |
| Journal | Journal of Neurology |
| Volume | 239 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1992 |
Fingerprint
Keywords
- Autoimmunity
- Cholinesterase inhibitors
- Intranasal administration
- Myasthenia gravis
- Neostigmine
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Cite this
Efficacy of intranasal administration of neostigmine in myasthenic patients. / Sghirlanzoni, Angelo; Pareyson, Davide; Benvenuti, Claudio; Cei, Giovanni; Cosi, Vittorio; Lombardi, Mariella; Nicora, Mariaflavia; Ricciardi, Roberta; Cornelio, Ferdinando.
In: Journal of Neurology, Vol. 239, No. 3, 03.1992, p. 165-169.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy of intranasal administration of neostigmine in myasthenic patients
AU - Sghirlanzoni, Angelo
AU - Pareyson, Davide
AU - Benvenuti, Claudio
AU - Cei, Giovanni
AU - Cosi, Vittorio
AU - Lombardi, Mariella
AU - Nicora, Mariaflavia
AU - Ricciardi, Roberta
AU - Cornelio, Ferdinando
PY - 1992/3
Y1 - 1992/3
N2 - The efficacy of intranasally administered neostigmine was tested in 22 patients with generalized myasthenia gravis (MG). Topical therapy to the highly vascularized oropharynx proved to be quickly effective in 5-15 min both clinically and electrophysiologically. Twenty-eight MG patients were then recruited from different centres and their morning doses of oral pyridostigmine were substituted with intranasal neostigmine over a period of 2 or 3 weeks. Intranasal neostigmine proved to be equally efficacious in this regimen. No side-effect was noted even in 4 patients treated in this way for 1 year. Intranasal administration of anti-acetylcholinesterase may be very beneficial: (1) for patients with irregular absorption of oral doses; (2) early in the morning and every time a fast and temporary effect is needed; (3) in bulbar impairment and emergencies, in which a handy atomizer may be life-saving.
AB - The efficacy of intranasally administered neostigmine was tested in 22 patients with generalized myasthenia gravis (MG). Topical therapy to the highly vascularized oropharynx proved to be quickly effective in 5-15 min both clinically and electrophysiologically. Twenty-eight MG patients were then recruited from different centres and their morning doses of oral pyridostigmine were substituted with intranasal neostigmine over a period of 2 or 3 weeks. Intranasal neostigmine proved to be equally efficacious in this regimen. No side-effect was noted even in 4 patients treated in this way for 1 year. Intranasal administration of anti-acetylcholinesterase may be very beneficial: (1) for patients with irregular absorption of oral doses; (2) early in the morning and every time a fast and temporary effect is needed; (3) in bulbar impairment and emergencies, in which a handy atomizer may be life-saving.
KW - Autoimmunity
KW - Cholinesterase inhibitors
KW - Intranasal administration
KW - Myasthenia gravis
KW - Neostigmine
UR - http://www.scopus.com/inward/record.url?scp=0026576374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026576374&partnerID=8YFLogxK
U2 - 10.1007/BF00833919
DO - 10.1007/BF00833919
M3 - Article
C2 - 1573422
AN - SCOPUS:0026576374
VL - 239
SP - 165
EP - 169
JO - Journal of Neurology
JF - Journal of Neurology
SN - 0340-5354
IS - 3
ER -